BCLI - Brainstorm to pull marketing application for ALS therapy
2023-10-18 13:28:57 ET
More on BrainStorm
- Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks
- Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2023 Earnings Call Transcript
- FDA advisory panel votes against BrainStorm ALS therapy
- BrainStorm stock halted as FDA panel reviews ALS therapy NurOwn
- Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics
For further details see:
Brainstorm to pull marketing application for ALS therapy